2025 China Anti-Asthmatics And Copd Drugs Market Revenue Opportunities Report
Description
The 2025 China Anti-Asthmatics And Copd Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthmatics and COPD Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Asthmatics and COPD drugs market in China are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and China National Pharmaceutical Group (Sinopharm). GSK has strengthened its COPD portfolio with a $12 billion collaboration with China's Hengrui Pharma, advancing multiple drug candidates including a PDE3/4 inhibitor to enhance bronchodilation and anti-inflammatory effects. AstraZeneca and Boehringer Ingelheim are recognized global leaders with growing footprints in China, focusing on addressing the rise in asthma and COPD prevalence driven by environmental factors such as air pollution and smoking. Sinopharm, as a leading Chinese pharmaceutical group, is a major domestic player leveraging local market access and production capabilities in asthma and COPD therapeutics.
These companies contribute significantly to the Chinese market's growth, which was valued at approximately $2.68 billion in 2022 and is expected to grow at a CAGR of about 6.7% through 2030. The market's expansion is propelled by increasing prevalence of respiratory diseases, rising economic growth, advancements in treatment options, and governmental health initiatives. International firms like GSK and AstraZeneca often engage in partnerships or licensing deals with local firms, exemplified by GSK's major upfront investment in Chinese research and development. This landscape reflects both global pharmaceutical innovation and China's growing role as a key therapeutics market for anti-asthmatics and COPD drugs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthmatics and COPD Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Asthmatics and COPD drugs market in China are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and China National Pharmaceutical Group (Sinopharm). GSK has strengthened its COPD portfolio with a $12 billion collaboration with China's Hengrui Pharma, advancing multiple drug candidates including a PDE3/4 inhibitor to enhance bronchodilation and anti-inflammatory effects. AstraZeneca and Boehringer Ingelheim are recognized global leaders with growing footprints in China, focusing on addressing the rise in asthma and COPD prevalence driven by environmental factors such as air pollution and smoking. Sinopharm, as a leading Chinese pharmaceutical group, is a major domestic player leveraging local market access and production capabilities in asthma and COPD therapeutics.
These companies contribute significantly to the Chinese market's growth, which was valued at approximately $2.68 billion in 2022 and is expected to grow at a CAGR of about 6.7% through 2030. The market's expansion is propelled by increasing prevalence of respiratory diseases, rising economic growth, advancements in treatment options, and governmental health initiatives. International firms like GSK and AstraZeneca often engage in partnerships or licensing deals with local firms, exemplified by GSK's major upfront investment in Chinese research and development. This landscape reflects both global pharmaceutical innovation and China's growing role as a key therapeutics market for anti-asthmatics and COPD drugs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
